Cabinet Office to Organize Society 5.0 Expo to Showcase Japan’s Advanced Technologies and Achievements
14.7.2021 09:00:00 EEST | Business Wire | Press release
The Government of Japan’s Cabinet Office announced that it will organize the Society 5.0 Expo jointly with the Japan Agency for Marine-Earth Science and Technology (JAMSTEC) from 15 July at TOKYO SKYTREE TOWN® in Tokyo, Japan. This is expected to be Japan’s first major expo to focus on Society 5.0. The expo will also be viewable online with multilingual explanations for the global audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713006253/en/
[From upper-left] SHINKAI 6500, HAYABUSA2, Wearable Cyborg, Active scope camera for rescue [From lower-left] Ultra-thin and flexible tough polymer, Rescue robot, Small synthetic-aperture radar satellite (SAR), Communication robot, Flying car, Level-3 autonomous vehicle (Photo: Business Wire)
The expo will showcase the Society 5.0 concept proposed by the Japanese government as a highly desirable future society. The concept envisions the creation of a human-centered society in which all industries and other areas of society adopt AI, IoT, robots, big data and other innovative technologies to overcome critical challenges. The Cabinet Office’s 6th Science, Technology and Innovation Basic Plan covering fiscal 2021 to 2025 sets forth the direction of science, technology and innovation policies to secure sustainability, resilience and the well-being of diverse individuals.
The expo will present achievements being realized through national projects focused on increasing innovation in society, including the cross-ministerial strategic innovation promotion program (SIP) and the ImPACT program for stimulating high-risk, high-impact R&D. Japan’s scientific and technological aspirations will be conveyed through numerous displays of advanced technologies.
Specifically, some 50 leading Japanese companies, universities and organizations will exhibit approximately 200 products and research achievements that are expected to contribute not only to Society 5.0 but also the UN’s Sustainable Development Goals. The exhibits will cover fields such as mobility, healthcare and caregiving, manufacturing, agriculture, food, disaster prevention and energy, including:
- Asteroid-explorer Hayabusa2’s returned capsule
- Full-scale model of SHINKAI 6500 submersible piloted to 6,500 meters undersea
- SkyDrive flying car
- Honda Legend Level-3 autonomous vehicle with high-definition 3D mapping
- Model of small synthetic-aperture radar satellite system for on-demand launches and instant observation
- HAL wearable cyborg that transmits brain signals to human muscles for assistance with physical functions
- Disaster-prevention systems for heavy rain and tornado forecasting and ICT-based information sharing
- Smart agriculture technology, such as an automated water supply and drainage system
International viewers will be welcome to enjoy the many exhibits viewable online via mobile devices and PCs, supported with explanations available in a number of languages. The organizers will be pleased to present the virtual exhibition as an opportunity for the global community to learn more about Japan’s forward-looking Society 5.0 concept.
Exhibits will be grouped under the follow themes:
Stage 1 Prologue
The opening theme will present a full-scale model of the SHINKAI 6500 research submersible and a Dagik Earth three-dimensional digital globe, etc. Satellite-based technologies that are being deployed on a practical working basis in various sectors also will be introduced.
Stage 2 Science Frontiers—Space and Ocean
Exhibits of Japan's world-class space-exploration technology will include models of the International Space Station, the "Kibo" Japanese Experiment Module, a full-scale rocket engine, and the Hayabusa2 return capsule.
Exhibits of Japan’s ocean exploration and environmental-simulation technology will include autonomous underwater vehicles for exploring hydrothermal vents and ocean-floor resources and advanced solutions for ocean research.
Stage 3 5.0 Society of the Future
Science and technologies developed through Japan’s SIP and ImPACT programs and how they will help to enhance life in five areas: 1) 100-year lifespans, 2) Mobility and social interaction, 3) Infrastructure for more resilient and safer life, 4) Human- and earth-friendly lifestyles and 5) Advanced manufacturing. Exhibits will include automated solutions such as robots, vehicles and drones, disaster-prevention systems such as AI for infrastructure inspections, robotic industrial borescopes, next-generation energy and resources such as ammonia fuel and ocean-floor minerals, and advanced materials such as synthetic spider silk and strong but flexible ultra-thin polymers.
Stage 4 Trajectory toward Society 5.0
The evolution of human civilization will be presented through videos and other visuals portraying Society 1.0 (hunting & gathering), 2.0 (agriculture), 3.0 (industry) and 4.0 (information) as well as 5.0 (at TOKYO SKYTREE® Tembo Galleria, the closest point to space in Tokyo).
Stage 5 Society 5.0 Theater
Films from the Japan Aerospace Exploration Agency (JAXA) and JAMSTEC will be aired. Also, researchers and experts will give presentations about science, oceans, disaster prevention and ICT for advanced technology and innovation.
Please download official images from here.
Outline of Society 5.0 Expo
|
Organizers |
Cabinet Office and Japan Agency for Marine-Earth Science and Technology (JAMSTEC) |
|
|
Venue |
Exhibition areas within TOKYO SKYTREE TOWN |
|
|
|
- Pavilion at TOKYO SKYTREE TOWN Sky Arena (4F) |
|
|
|
- TOKYO SKYTREE TOWN Solamachi Square (1F) |
|
|
|
- TOKYO SKYTREE Group Floor (1F) |
|
|
|
- TOKYO SKYTREE Tembo Galleria |
|
|
|
- TOKYO SKYTREE TOWN campus of Chiba Institute of Technology |
|
|
|
|
|
|
Dates |
15 July to 5 September 2021 |
|
|
|
- Physical exhibitions by enterprises (15 July to 19 July) |
|
|
|
- Physical exhibitions by other organizations (15 July to 28 July) |
|
|
|
- Sub-exhibition by posters and videos (15 July to 5 September) |
|
|
|
- Virtual exhibition (17 July to 5 September) with multi-language explanations
|
|
|
Admission |
Free (Admission to sub-exhibition by ticket, sold at TOKYO SKYTREE Tembo Galleria) |
|
|
Exhibitors and partners |
Please refer to the list on the official website |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006253/en/
Contact information
Society 5.0 media inquiries
Weber Shandwick
Mayuko Harada (+81-90-9006-4968)
Rina Uesugi (+81-90-2280-0041)
E-mail: society5.0expo@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom